Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Nikhil Wagle, M.D.

Co-Author

This page shows the publications co-authored by Nikhil Wagle and Gad Getz.
Connection Strength

0.847
  1. Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014 Oct 09; 371(15):1426-33.
    View in: PubMed
    Score: 0.148
  2. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2014 Jan; 4(1):61-8.
    View in: PubMed
    Score: 0.139
  3. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clin Cancer Res. 2020 06 01; 26(11):2556-2564.
    View in: PubMed
    Score: 0.054
  4. Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018 09; 8(9):1096-1111.
    View in: PubMed
    Score: 0.048
  5. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2018 02 20; 36(6):543-553.
    View in: PubMed
    Score: 0.046
  6. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017 11 06; 8(1):1324.
    View in: PubMed
    Score: 0.046
  7. Systematic genomic and translational efficiency studies of uveal melanoma. PLoS One. 2017; 12(6):e0178189.
    View in: PubMed
    Score: 0.045
  8. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2015 May; 1(2):238-44.
    View in: PubMed
    Score: 0.039
  9. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discov. 2015 Apr; 5(4):358-67.
    View in: PubMed
    Score: 0.038
  10. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A. 2014 Dec 23; 111(51):E5564-73.
    View in: PubMed
    Score: 0.038
  11. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 2014 Oct; 4(10):1140-53.
    View in: PubMed
    Score: 0.037
  12. Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Mol Cancer. 2014 Jun 04; 13:141.
    View in: PubMed
    Score: 0.036
  13. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014 Jun; 20(6):682-8.
    View in: PubMed
    Score: 0.036
  14. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014 Jan; 4(1):94-109.
    View in: PubMed
    Score: 0.035
  15. A landscape of driver mutations in melanoma. Cell. 2012 Jul 20; 150(2):251-63.
    View in: PubMed
    Score: 0.032
  16. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012 May 09; 485(7399):502-6.
    View in: PubMed
    Score: 0.031
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.